Scilex Holding Co (SCLXW) — SEC Filings
Scilex Holding Co (SCLXW) — 50 SEC filings. Latest: 8-K (Dec 30, 2025). Includes 38 8-K, 4 10-Q, 3 DEF 14A.
View Scilex Holding Co on SEC EDGAR
Overview
Scilex Holding Co (SCLXW) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 22, 2025: Scilex Holding Company filed an 8-K on December 22, 2025, reporting information related to its common stock and warrants. The filing details the par value of its common stock as $0.00001 per share and the exercise price of its warrants to purchase common stock at $4.0250 per share.
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 5 bearish, 45 neutral. The dominant filing sentiment for Scilex Holding Co is neutral.
Filing Type Overview
Scilex Holding Co (SCLXW) has filed 38 8-K, 2 S-1, 4 10-Q, 3 DEF 14A, 1 10-K/A, 1 10-K, 1 8-K/A with the SEC between Nov 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of SCLXW's 43 recent filings, 5 were flagged as high-risk, 24 as medium-risk, and 14 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $10.56M |
| Net Income | -$257.82M |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | N/A |
| Operating Margin | N/A |
| Total Assets | $275.88M |
| Total Debt | $455.60M |
Key Executives
- Henry Ji, Ph.D.
- Jeffrey T. Hartlin, Esq.
- Elizabeth A. Razzano, Esq.
- Stephen Ma
- Dr. Anthony L. Carbone
- Mr. David R. Glick
- Mr. Robert E. Diamond
- Mr. David M. S. Johnson
Industry Context
Scilex Holding Company operates in the pharmaceutical sector, focusing on pain management and other areas. The industry is characterized by high R&D costs, lengthy regulatory approval processes, and intense competition from both large established players and smaller biotech firms. Market trends include a growing demand for innovative treatments, particularly for chronic conditions, but also increasing pricing pressures and scrutiny from payers.
Top Tags
filing (9) · 8-K (6) · material-agreement (6) · financials (6) · warrants (5) · Biotechnology (5) · Pharmaceuticals (3) · Net Loss (3) · disclosure (3) · stock-details (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Common Stock Par Value | $0.00001 | Represents the nominal value per share of Scilex's common stock. |
| Warrant Exercise Price | $4.0250 | The price at which holders can exercise their warrants to purchase one share of common stock. |
| Last reported sales price per share of Common Stock | $16.63 | As of December 12, 2025, significantly below several warrant exercise prices. |
| Shares of Common Stock issuable upon exercise of Exchange Warrants | 500,000 | Issued on July 28, 2025, at an exercise price of $40.00 per share. |
| Exercise price per share for Exchange Warrants | $40.00 | Higher than the current market price of $16.63. |
| Shares of Common Stock offered for resale by Selling Stockholders | 1,703,946 | Comprises September 2025 and November 2025 Warrant Shares, representing potential dilution. |
| Shares of Common Stock issuable upon exercise of September 2025 Warrants | 275,000 | Issued on September 30, 2025, at an exercise price of $20.00 per share. |
| Exercise price per share for September 2025 Warrants | $20.00 | Slightly above the current market price of $16.63. |
| Shares of Common Stock issuable upon exercise of November 2025 Investor Warrant | 1,356,594 | Issued on November 25, 2025, at an exercise price of $29.00 per share. |
| Exercise price per share for November 2025 Investor Warrant and Placement Agent Warrants | $29.00 | Significantly higher than the current market price of $16.63. |
| Reverse Stock Split ratio | 1-for-35 | Effected on April 15, 2025, impacting per-share metrics. |
| Shares of Common Stock issuable upon exercise of November 2025 Placement Agent Warrants | 72,352 | Issued on November 25, 2025, at an exercise price of $29.00 per share. |
| Net Loss (Q3 2025) | $257.82M | Increased significantly from $4.39M in Q3 2024, indicating worsening financial performance. |
| Net Revenue (Q3 2025) | $10.56M | Decreased from $14.44M in Q3 2024, showing a decline in core business sales. |
| Selling, General & Administrative Expenses (Q3 2025) | $188.82M | Massive increase from $29.73M in Q3 2024, a primary driver of the expanded net loss. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Scilex Holding Co (SCLXW)?
Scilex Holding Co has 50 recent SEC filings from Nov 2024 to Dec 2025, including 38 8-K, 4 10-Q, 3 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of SCLXW filings?
Across 50 filings, the sentiment breakdown is: 5 bearish, 45 neutral. The dominant sentiment is neutral.
Where can I find Scilex Holding Co SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Scilex Holding Co (SCLXW) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Scilex Holding Co?
Key financial highlights from Scilex Holding Co's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for SCLXW?
The investment thesis for SCLXW includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Scilex Holding Co?
Key executives identified across Scilex Holding Co's filings include Henry Ji, Ph.D., Jeffrey T. Hartlin, Esq., Elizabeth A. Razzano, Esq., Stephen Ma, Dr. Anthony L. Carbone and 3 others.
What are the main risk factors for Scilex Holding Co stock?
Of SCLXW's 43 assessed filings, 5 were flagged high-risk, 24 medium-risk, and 14 low-risk.
What are recent predictions and forward guidance from Scilex Holding Co?
Forward guidance and predictions for Scilex Holding Co are extracted from SEC filings as they are enriched.